Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer - Trial NCT05600127
Access comprehensive clinical trial information for NCT05600127 through Pure Global AI's free database. This Phase 2 trial is sponsored by Erasmus Medical Center and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Erasmus Medical Center
Timeline & Enrollment
Phase 2
Dec 01, 2022
Dec 01, 2026
Primary Outcome
Pathological complete response rate
Summary
Patients with locally advanced or clinically node positive urothelial carcinoma treated with
 chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05600127
Non-Device Trial